Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer

Ureter Carcinoma

Eli Lilly and Companymonoclonal_antibodyPhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Ureter Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Icrucumab Eli Lilly and Company	Phase 2	B
Docetaxel Eli Lilly and Company	Phase 2	B
Rucaparib pharmaand GmbH	Phase 2	CCC

Same molecule, other indications

Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer is also rated in:

urothelial carcinomaDormant

Indicative · Phase 3

68 / 100

View asset →

hepatocellular carcinomaActive

Indicative · Phase 3

65 / 100

View asset →

lung cancerActive

Indicative · Phase 3

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →